Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement

US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.

antibiotics, pills and injection

US FDA Commissioner Scott Gottlieb chose to focus on antimicrobial reimbursement ideas rather than development policy in his announcement of new draft guidance on the Limited Population Antibacterial Drug (LPAD) pathway that was issued June 12.

LPAD is designed to speed approvals of novel antibiotics for small populations with serious or life-threatening conditions. (See sidebar.)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet